טוען...
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse
The risk of central nervous system (CNS) dissemination in mantle cell lymphoma (MCL) is low and occurs late in the course of the disease. However, prognosis in such cases remains extremely poor despite high-dose antimetabolite chemotherapy. Among novel drugs used to treat relapsing MCL patients, ibr...
שמור ב:
| הוצא לאור ב: | Blood |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Hematology
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4591793/ https://ncbi.nlm.nih.gov/pubmed/26239089 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-647834 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|